Current and historical daily PE Ratio for Opthea Ltd (
FRA:UKJ
) from 2017 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Opthea stock (FRA:UKJ) PE ratio as of Apr 25 2024 is 0.
More Details
Opthea Ltd (FRA:UKJ) PE Ratio (TTM) Chart
Opthea Ltd (FRA:UKJ) PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Total 1252
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Opthea PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-12 | At Loss |
| 2024-03-15 | At Loss | 2024-01-11 | At Loss |
| 2024-03-14 | At Loss | 2024-01-10 | At Loss |
| 2024-03-13 | At Loss | 2024-01-09 | At Loss |
| 2024-03-12 | At Loss | 2024-01-08 | At Loss |
| 2024-03-11 | At Loss | 2024-01-05 | At Loss |
| 2024-03-08 | At Loss | 2024-01-04 | At Loss |
| 2024-03-07 | At Loss | 2024-01-03 | At Loss |
| 2024-03-06 | At Loss | 2024-01-02 | At Loss |
| 2024-03-05 | At Loss | 2023-12-29 | At Loss |
| 2024-03-04 | At Loss | 2023-12-28 | At Loss |
| 2024-03-01 | At Loss | 2023-12-27 | At Loss |
| 2024-02-29 | At Loss | 2023-12-22 | At Loss |
| 2024-02-28 | At Loss | 2023-12-21 | At Loss |
| 2024-02-27 | At Loss | 2023-12-20 | At Loss |
| 2024-02-26 | At Loss | 2023-12-19 | At Loss |
| 2024-02-23 | At Loss | 2023-12-18 | At Loss |
| 2024-02-22 | At Loss | 2023-12-15 | At Loss |
| 2024-02-21 | At Loss | 2023-12-14 | At Loss |
Opthea Ltd (FRA:UKJ) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Opthea Ltd
NAICS : 325412
SIC : 2834
ISIN : AU000000OPT2
Compare
Compare
Traded in other countries / regions
OPT.AustraliaOPT.USAUKJ.Germany IPO Date
2017-04-11Description
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers